MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Aurinia Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

11.55 0.17

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.51

Massimo

11.58

Metriche Chiave

By Trading Economics

Entrata

-1.8M

22M

Vendite

7.5M

70M

P/E

Media del settore

25.814

36.442

Margine di Profitto

30.729

Dipendenti

130

EBITDA

6.3M

28M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+1.04% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

260M

1.5B

Apertura precedente

11.38

Chiusura precedente

11.55

Notizie sul Sentiment di mercato

By Acuity

11%

89%

7 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Aurinia Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 ott 2025, 20:00 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

19 ott 2025, 23:44 UTC

Discorsi di Mercato

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

19 ott 2025, 23:37 UTC

Discorsi di Mercato

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

19 ott 2025, 23:36 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

19 ott 2025, 23:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

19 ott 2025, 23:09 UTC

Discorsi di Mercato

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

19 ott 2025, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

19 ott 2025, 22:30 UTC

Utili

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

19 ott 2025, 22:18 UTC

Discorsi di Mercato

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

19 ott 2025, 21:50 UTC

Discorsi di Mercato

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

19 ott 2025, 21:15 UTC

Discorsi di Mercato

Investors Need to Change Narrative Toward Scales -- Market Talk

19 ott 2025, 19:34 UTC

Acquisizioni, Fusioni, Takeovers

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

19 ott 2025, 19:34 UTC

Acquisizioni, Fusioni, Takeovers

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

19 ott 2025, 19:33 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

19 ott 2025, 19:32 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

19 ott 2025, 19:32 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

19 ott 2025, 19:31 UTC

Acquisizioni, Fusioni, Takeovers

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

19 ott 2025, 19:31 UTC

Acquisizioni, Fusioni, Takeovers

Infratil to Acquire Additional 4.92% Stake in Contact Energy

19 ott 2025, 16:29 UTC

Utili

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

19 ott 2025, 11:14 UTC

Utili

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

19 ott 2025, 11:14 UTC

Utili

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

19 ott 2025, 11:14 UTC

Utili

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 ott 2025, 13:30 UTC

Acquisizioni, Fusioni, Takeovers

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 ott 2025, 08:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

17 ott 2025, 23:25 UTC

Acquisizioni, Fusioni, Takeovers

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 ott 2025, 22:15 UTC

Discorsi di Mercato

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 ott 2025, 21:15 UTC

Discorsi di Mercato

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Confronto tra pari

Modifica del prezzo

Aurinia Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

1.04% in crescita

Previsioni per 12 mesi

Media 11.67 USD  1.04%

Alto 17 USD

Basso 9 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Aurinia Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

5

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

8.1 / 8.21Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

7 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
help-icon Live chat